Detoxification From the Lipid Tract

Pachankis, Yang I., M.D.

Status and phase: Completed; Phase 4

Conditions: COVID-19 Vaccine Adverse Reaction

Treatments: Drug: Alprazolam; Device: electroencephalogram biofeedback; Device: ultra-low frequency transcranial magnetic stimulation; Drug: Pravastatin Sodium 20 MG; Drug: Clonazepam; Drug: Sacubitril Valsartan Sodium Hydrate; Drug: Metoprolol; Drug: Sertraline Hydrochloride; Drug: Olanzapine; Device: electrical brain stimulation

Study type: Interventional

Funder types: Other

Identifiers

NCT06357104

SCI-CT-0001

Details and patient eligibility

About

Apart from electroencephalogram biofeedback and electrical brain stimulation adopted for maintenance treatment, the study utilizes ultra-low frequency transcranial magnetic stimulation (ULF-TMS) for initial γ-aminobutyric acid (GABA) stimulation. The cocktail therapy starts after the primary efficacy endpoint, and concomitant therapy is adopted throughout the study.

Full description

It was tested that GABA, in the joint action with topiramate, modulates macrophage activities by modulating cholesterol-metabolism associated molecules. GABA A receptors exhibit highly dynamic trafficking and cell surface mobility and influence on post-endocytic effects. Benzodiazepines (BZDs) exercise the mechanism of action by facilitating the binding of the inhibitory neurotransmitter GABA at various GABA receptors throughout the central nervous system (CNS). Alprazolam, a type of BZD, was tested by Al-Tubuly, Aburawi, Alghzewi, Gorash and Errwami in joint action with water-soluble beta blocker atenolol, in comparison with the non-selective β-adrenoceptor antagonist propranolol on the pharmacological effects on depression. The study hypothesizes that by replacing the water-soluble beta blocker to lipid-soluble one metoprolol, the effect of detoxification from the lipid and sebaceous immunobiological pathways can be achieved by the clathrin-dependent endocytosis process.

Even though partial progress was made in the NCT05839236 trial by statin therapies, the therapeutic effects have not been lasting nor significant. The study develops from the previous protocol for a cocktail therapy by the joint mechanism of actions of alprazolam, metoprolol, and pravastatin sodium for the detoxification process.

Enrollment: 1 patient

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• People who received full doses of COVID-19 vaccines.

Exclusion criteria

• Women during pregnancy.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

1 participants in 1 patient group

GABA Cocktail

Experimental group

Treatment:

Drug: Clonazepam

Drug: Pravastatin Sodium 20 MG

Drug: Alprazolam

Device: electrical brain stimulation

Drug: Sacubitril Valsartan Sodium Hydrate

Drug: Metoprolol

Drug: Sertraline Hydrochloride

Drug: Olanzapine

Device: ultra-low frequency transcranial magnetic stimulation

Device: electroencephalogram biofeedback